Kisqali (ribociclib) given alongside endocrine therapy ... for approval of Kisqali in the new indication later this year. AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder ...

Patients would have to wait to access the treatment, however, as the FDA would not approve AstraZeneca’s Nolvadex ... The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved ...

Welcome, ladies and gentlemen, to AstraZeneca's Investor Conference Call ESMO 2024. Before I hand over to AstraZeneca's management team, I'd like to read the safe harbor statement. The Company ...

Sept 16 (Reuters) - Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...

"System errors" meant a man who died after being given the AstraZeneca Covid-19 vaccine was wrongly invited to have the jab, an independent report has found. Jack Last, 27, an engineer from ...

A healthy 27-year-old died from a reaction to the AstraZeneca Covid vaccine after NHS mistakes meant he wrongly got the jab, a report has found. Jack Last, from Stowmarket in Suffolk, died because ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...